Literature DB >> 23235651

Screening for oesophageal cancer.

Shujuan Yang1, Siying Wu, Yuchuan Huang, Ying Shao, Xiao Y Chen, Liu Xian, Jianwei Zheng, Yuanyuan Wen, Xinyue Chen, Huangyuan Li, Chunxia Yang.   

Abstract

BACKGROUND: Oesophageal cancer is a global heath problem. The prognosis for advanced oesophageal cancer is generally unfavourable, but early-stage asymptomatic oesophageal cancer is basically curable and could achieve better survival rates. The two most commonly used tests are cytologic examination and endoscopy with mucosal iodine staining. The efficacy of the screening tests is controversial, and the true benefit and efficacy of screening remains uncertain because of the potential lead-time and length-time biases. This review was conducted to examine the evidence for the efficacy of screening for oesophageal cancer (squamous cell carcinoma and adenocarcinoma).
OBJECTIVES: To determine the efficacy of early screening, using endoscopy with iodine staining or cytologic examination, in reducing mortality from oesophageal cancer in asymptomatic individuals from high-risk and general populations. SEARCH
METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 8), The Cochrane Library (2012, Issue 8), MEDLINE (1950 to August 2012), EMBASE (1980 to August 2012), Allied and Complementary Medicine (AMED) (1985 to August 2012), Chinese Biomedical Database (CBM) (January 1975 to August 2012), VIP Database (January 1989 to August 2012), China National Knowledge Infrastructure (CNKI) (January 1979 to August 2012), and the Internet. We also searched reference lists, conference proceedings, and databases of ongoing trials. There was no restriction on language or publication status in the search for trials. SELECTION CRITERIA: We included only randomised controlled trials (RCT) of screening versus no screening for oesophageal cancer. Randomisation of groups or clusters of individuals was acceptable. DATA COLLECTION AND ANALYSIS: Two review authors independently scanned the titles and abstracts from the initial search for potential trials for inclusion. We did not find any trials that met the inclusion criteria. MAIN
RESULTS: The electronic search identified 3482 studies. Two authors independently reviewed the references. The reports of 18 studies were retrieved for further investigation. None met the eligibility criteria for a RCT investigation of the effects of screening versus no screening for oesophageal cancer. AUTHORS'
CONCLUSIONS: There were no RCTs that determined the efficacy of screening for oesophageal cancer. Non-RCTs showed a high incidence and the reported better survival after screening could be caused by selection bias, lead-time and length-time biases. RCTs are needed to determine the efficacy of screening for oesophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23235651     DOI: 10.1002/14651858.CD007883.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  12 in total

Review 1.  How to transfer traditional knowledge about medicinal herbs? or TCM plants: a black box for modern oncologists.

Authors:  Judith Büntzel; Oliver Micke; Jens Büntzel
Journal:  J Cancer Res Clin Oncol       Date:  2020-10-10       Impact factor: 4.553

2.  Editorial: The Effect of Bias on Estimation of Improved Survival After Diagnosis of Barrett's Esophagus.

Authors:  Liam Zakko; Kavel Visrodia; Kenneth K Wang; Prasad G Iyer
Journal:  Am J Gastroenterol       Date:  2017-08       Impact factor: 10.864

Review 3.  Interventions for dysphagia in oesophageal cancer.

Authors:  Yingxue Dai; Chaoying Li; Yao Xie; Xudong Liu; Jianxin Zhang; Jing Zhou; Xiongfei Pan; Shujuan Yang
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30

4.  Inhibition of human positive cofactor 4 radiosensitizes human esophageal squmaous cell carcinoma cells by suppressing XLF-mediated nonhomologous end joining.

Authors:  D Qian; B Zhang; X-L Zeng; J M Le Blanc; Y-H Guo; C Xue; C Jiang; H-H Wang; T-S Zhao; M-B Meng; L-J Zhao; J-H Hao; P Wang; D Xie; B Lu; Z-Y Yuan
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

Review 5.  Managing the changing burden of cancer in Asia.

Authors:  Rengaswamy Sankaranarayanan; Kunnambath Ramadas; You-lin Qiao
Journal:  BMC Med       Date:  2014-01-08       Impact factor: 8.775

6.  The Spatial Predilection for Early Esophageal Squamous Cell Neoplasia: A "Hot Zone" for Endoscopic Screening and Surveillance.

Authors:  Wen-Lun Wang; I-Wei Chang; Chien-Chuan Chen; Chi-Yang Chang; Jaw-Town Lin; Lein-Ray Mo; Hsiu-Po Wang; Ching-Tai Lee
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 7.  Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett's esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: two systematic reviews and one overview of reviews to inform a guideline of the Canadian Task Force on Preventive Health Care (CTFPHC).

Authors:  Candyce Hamel; Nadera Ahmadzai; Andrew Beck; Micere Thuku; Becky Skidmore; Kusala Pussegoda; Lise Bjerre; Avijit Chatterjee; Kristopher Dennis; Lorenzo Ferri; Donna E Maziak; Beverley J Shea; Brian Hutton; Julian Little; David Moher; Adrienne Stevens
Journal:  Syst Rev       Date:  2020-01-29

Review 8.  Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers.

Authors:  Mukulika Bose; Pinku Mukherjee
Journal:  Vaccines (Basel)       Date:  2020-11-05

9.  The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis.

Authors:  Baohua Huang; Lei Chen; Cuixia Bao; Chengming Sun; Jie Li; Lipeng Wang; Xia Zhang
Journal:  Onco Targets Ther       Date:  2015-09-15       Impact factor: 4.147

10.  Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran.

Authors:  G Roshandel; S Merat; M Sotoudeh; M Khoshnia; H Poustchi; P Lao-Sirieix; S Malhotra; M O'Donovan; A Etemadi; A Nickmanesh; A Pourshams; A Norouzi; I Debiram; S Semnani; C C Abnet; S M Dawsey; R C Fitzgerald; R Malekzadeh
Journal:  Br J Cancer       Date:  2014-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.